Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
308080.KQ
STRONG SELLViGenCell Inc. · Healthcare · South Korea · $135M · Avg Vol: $4M/d
12
StockRankQ
32
V
37
M
29
P/E (TTM)
—
ROE
-20.2%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD...
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | 183,619 | 14,926 | -91.9% |
| EPS | -0.21 | -0.60 | -0.62 | -0.48 | — | — |
| Shares | — | 19M | 19M | 19M | 20M | +7.6% |
| Debt | — | 5M | 5M | 5M | 5M | 0.1% |
| Equity | — | 59M | 47M | 38M | 29M | -21.3% |
| Op CF | — | -7M | -10M | -7M | -9M | — |
| Inv CF | — | -7M | 16M | 3M | 3M | — |
| Fin CF | — | -1M | 195,280 | 111,560 | 1M | — |
Loading...
PRICE (1M)-31.0%
SMA 50SMA 200
Close
$4.79
RSI (14)
12.2
52W High
$11.43
From 52W High
0.4%
SCORE BREAKDOWN
Quality
32
ROIC
-30.4%22.6
ROE
-20.2%29.8
GP/Assets
0.0%10.0
Op. Margin
-4861.7%3.4
FCF/Assets
-8.8%29.6
Piotroski
—28.7
Int. Cover
-50.0x6.4
D/E Ratio
0.14x61.0
Current Ratio
5.77x75.1
Value
37
P/E (TTM)
—N/A
EV/EBITDA
-16.2x85.7
P/FCF
—N/A
P/B
3.1x38.5
P/S
737.5x3.0
Div Yield
—N/A
Momentum
29
52W High %
42%14.6
RS 6M
-164%1.5
SMA 50/200
1.32x94.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$135M
P/E (Forward)
—
Gross Margin
1.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 308080.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 308080.KQ | ViGenCell Inc.(you) | $135M | 12 | STRONG SELL |
| 138610.KQ | NIBEC Co., Ltd. | $141M | 14 | STRONG SELL |
| 115450.KQ | HLB Therapeutics Co.,Ltd. | $147M | 15 | STRONG SELL |
| 321550.KQ | TiumBio Co., Ltd. | $127M | 7 | STRONG SELL |
| 308430.KQ | Cellbion | $150M | 8 | STRONG SELL |
| 314130.KQ | Genome & Company | $146M | 16 | STRONG SELL |
| 394800.KQ | 3billion | $154M | 6 | STRONG SELL |
| 338840.KQ | Y-Biologics | $136M | 3 | STRONG SELL |
| 095700.KQ | Genexine, Inc. | $111M | 7 | STRONG SELL |
| 389650.KQ | NEXTBIOMEDICAL | $217M | 12 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%